1-(1-ethyl-4-(hydroxymethyl)-1H-imidazol-2-yl)ethanone | 1331754-29-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(1-ethyl-4-(hydroxymethyl)-1H-imidazol-2-yl)ethanone
• 英文别名: 1-[1-Ethyl-4-(hydroxymethyl)imidazol-2-yl]ethanone
• CAS: 1331754-29-0
• 化学式: C₈H₁₂N₂O₂
• 分子量: 168.195
• InChiKey: JOKYSFLKWRXZLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Imidazole Derivative
  申请人：Machinaga Nobuo

  公开号：US20120316170A1

  公开（公告）日：2012-12-13

  To provide a novel compound or an isotope thereof or a pharmaceutically acceptable salt thereof having S1P lyase inhibitory capacity and inducing the decrease in number of lymphocytes, and a pharmaceutical composition containing these as active ingredients. A compound represented by the general formula (I): or the general formula (II): or an isotope thereof or a pharmaceutically acceptable salt thereof.

  提供具有S1P裂解酶抑制能力并诱导淋巴细胞数量减少的新型化合物或其同位素或其药用可接受盐，以及含有这些化合物作为活性成分的药物组合物。由一般式(I)表示的化合物： 或一般式(II)： 或其同位素或其药用可接受盐。
• IMIDAZOLE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2537831B1

  公开（公告）日：2014-12-03
• ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY
  申请人：AC BioScience

  公开号：EP3668506A1

  公开（公告）日：2020-06-24
• US8653126B2
  申请人：——

  公开号：US8653126B2

  公开（公告）日：2014-02-18
• [EN] ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY<br/>[FR] AMÉLIORATION DE L'EFFICACITÉ DE TRAITEMENT DU CANCER PAR L'INTERMÉDIAIRE DE LA VOIE SPHINGOSINE-1-PHOSPHATE
  申请人：AC BIOSCIENCE

  公开号：WO2019034768A1

  公开（公告）日：2019-02-21

  The present invention relates to neoadjuvant prior to chemotherapy. The present invention relates to sphingosine-1-phosphate pathway activator for use in the treatment of cancer as neoadjuvant prior to chemotherapy selected from sphingosine-1-phosphate lyase inhibitors. The sphingosine-1-phosphate pathway activator enhances the chemotherapy efficiency through the normalization of intratumoral vascular network, promoting the effects of the sequential administration of an anticancer agent or a sequential radiotherapy.